%0 Journal Article
%T 非小细胞肺癌小分子的靶向治疗研究进展<br>Research Progress on Small Molecules Targeted Therapy in Non-Small Cell Lung Cancer
%A 申越
%A 王睿
%A 高婧
%A 尹楠
%A 王文杰
%A 曹荣月
%J World Journal of Cancer Research
%P 90-98
%@ 2164-9057
%D 2022
%I Hans Publishing
%R 10.12677/WJCR.2022.122012
%X 肺癌是全球范围内癌症首位致死率的恶性肿瘤，其中主要为非小细胞肺癌(NSCLC)。肺癌各类小分子靶标已经成为靶向药物研发和临床治疗的研究热点，以表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)等为代表的分子靶向药物通过阻止重要细胞信号传递，遏制肿瘤细胞生长增殖从而控制癌症进展。本文主要综述目前NSCLC中明确的分子途径及相应分子靶向治疗药物的进展。<br />
Lung cancer is a malignant tumor with the highest mortality in the world, and non-small cell lung cancer (NSCLC) is the most common type. There are more and more researches on molecular targets for lung cancer, leading to the rapid development of various molecular targeted drugs. Molecular targeted drugs such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR- TKI) block important pathways that drive cancer progression and achieve long-term disease control. This review summarizes the most important molecular pathways in NSCLC and describes the development of therapeutic drugs against these targets.
%K 非小细胞肺癌，分子靶向治疗，受体酪氨酸激酶抑制剂<br>Non-Small Cell Lung Cancer
%K Molecular Targeted Therapy
%K Tyrosine Kinase Inhibitors (TKIs)
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=50966